Thalia Therapeutics Plc (AIM:THAT)
London · Delayed Price · Currency is GBP · Price in GBX 0.6250
0.00 (0.00%)
Sep 4, 2026, 10:36 AM GMT
Thalia Therapeutics Market Cap
Thalia Therapeutics has a market cap or net worth of 5.2 million as of September 4, 2026. Its market cap has increased by 8.70% in one year.
Market Cap
5.20M
Enterprise Value
4.12M
Revenue
7.26K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.63
ChartMarket Cap Chart
Since May 3, 2017, Thalia Therapeutics's market cap has increased from 4.57M to 5.20M, an increase of 13.78%. That is a compound annual growth rate of 1.39%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 4, 2026 | 5.20M | 19.05% |
| Dec 31, 2025 | 4.37M | 110.82% |
| Dec 31, 2024 | 2.07M | -9.28% |
| Dec 29, 2023 | 2.28M | -47.18% |
| Dec 30, 2022 | 4.32M | -46.33% |
| Dec 31, 2021 | 8.06M | -46.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| May 3, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Aptamer Group | 12.09M |
| Genflow Biosciences | 11.61M |
| Solvonis Therapeutics | 8.00M |
| Cizzle Biotechnology Holdings | 6.37M |
| CRISM Therapeutics | 6.10M |
| OptiBiotix Health | 5.84M |
| Oxford BioDynamics | 5.15M |
| Nuformix | 4.14M |